TVTX

NASDAQ · Biotechnology

Travere Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$48.97

-3.45 (-6.58%)

TVTX News1 articles

Vera Therapeutics Gains as FDA Nod for Trutakna Puts Focus on Q3 Kidney Data

Vera Therapeutics (NASDAQ:VERA) shares climbed 7% following FDA accelerated approval of Trutakna for IgA nephropathy. The next key catalyst is Q3 2026 eGFR data from the ORIGIN 3 trial.